Suvorexant (MK-4305) CAS 1030377-33-3 Purity ≥98.0% (HPLC) e.e. ≥97.0%
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Suvorexant (MK-4305) (CAS: 1030377-33-3) with high quality. Suvorexant is a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia.
Ruifu Chemical has been supplying pharmaceutical intermediates and APIs, fine chemicals more than 15 years.
Ruifu Chemical can provide worldwide delivery, competitive price, excellent service.
Purchase Suvorexant (MK-4305) or other products, please contact us by e-mail: alvin@ruifuchem.com
Chemical Name | Suvorexant |
Synonyms | MK-4305; MK 4305; [(7R)-4-(5-Chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]-methanone; 5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole; (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; [(R)-4-(5-Chloro-benzooxazol-2-yl)-7-methyl-[1,4]diazepan-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; |
CAS Number | 1030377-33-3 |
Molecular Formula | C23H23ClN6O2 |
Molecular Weight | 450.92 g/mol |
Melting Point | 153℃ |
Density | 1.41 |
Storage Temperature | Store Long-Term at 2-8℃, Refrigerator |
Shipping Conditions | Ambient |
COA & MSDS | Available |
Origin of Product | Shanghai, China |
Product Categories |
Dual Orexin Receptor Antagonist (DORA) |
Caution | Not For Human or Veterinary Use. For Research Use Only. |
Expiration Date | 12 Months From Date of Receipt |
Brand | Ruifu Chemical |
Items | Specifications | Results |
Appearance | Off-White to Pink Solid | Conforms |
Identification | 1H NMR spectrum of sample corresponds to that of standard preparation | Conforms |
Mass spectrum of sample corresponds to that of standard preparation | Conforms | |
The retention time of the major peak in the chromatogram of sample corresponds to that in the chromatogram of standard preparation |
Conforms | |
Purity | >98.0% (HPLC) | 98.95% |
e.e. | ≥97.0% (by intermediate HM-148_010) | 97.27% |
Conclusion | The product has been tested and complies with the given specifications |
Package: Bottle, Aluminium foil bag, 25kg/cardboard drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃), well-ventilated warehouse away from incompatible substances. Keep away from sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Suvorexant (MK-4305) (CAS: 1030377-33-3) is a potent antagonist of OX1 receptor and OX2 receptor with Ki values of 0.55 nM and 0.35 nM, respectively. Suvorexant is a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation.
Suvorexant is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. Formulations containing suvorexant show abuse potential similar to zolpidem in recreational polydrug users with a history of sedative and psychedelic drug use.
On April 14, 2023, the Announcement of the National Medical Products Administration, the Ministry of Public Security and the National Health Commission on the adjustment of the List of Narcotic drugs and psychotropic Drugs clearly stated: "Suvorexan, Perampanel, Eptazocine, Tramadol compound preparations are included in the second category of psychotropic drugs list." The announcement shall take effect as of July 1, 2023.
Not For Human or Veterinary Use. For Research Use Only.